228P The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: An exploratory analysis of the CLEOPATRA trial

MLA

V. Debien, et al. “228P The Impact of Initial Tumor Response to Docetaxel, Trastuzumab, and Pertuzumab on Survival Outcomes of Patients with HER2+ Metastatic Breast Cancer: An Exploratory Analysis of the CLEOPATRA Trial.” ESMO Open, vol. 8, May 2023, p. 101417. EBSCOhost, https://doi.org/10.1016/j.esmoop.2023.101417.

APA

V. Debien, E. Agostinetto, M. Bruzzone, M. Ceppi, C. Molinelli, D. Martins Branco, F. Jacobs, G. Nader Marta, M. Lambertini, & E. de Azambuja. (2023). 228P The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: An exploratory analysis of the CLEOPATRA trial. ESMO Open, 8, 101417. https://doi.org/10.1016/j.esmoop.2023.101417

Chicago

V. Debien, E. Agostinetto, M. Bruzzone, M. Ceppi, C. Molinelli, D. Martins Branco, F. Jacobs, G. Nader Marta, M. Lambertini, and E. de Azambuja. 2023. “228P The Impact of Initial Tumor Response to Docetaxel, Trastuzumab, and Pertuzumab on Survival Outcomes of Patients with HER2+ Metastatic Breast Cancer: An Exploratory Analysis of the CLEOPATRA Trial.” ESMO Open 8 (May): 101417. doi:10.1016/j.esmoop.2023.101417.